Apixaban versus Warfarin in Patients with Atrial Fibrillation [PDF]
New England Journal of Medicine, 2011 BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a ...
Christopher B Granger +2 more
exaly +3 more sources
Apixaban for Extended Treatment of Venous Thromboembolism [PDF]
New England Journal of Medicine, 2013 Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism.In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 ...
Giancarlo Agnelli +2 more
exaly +11 more sources
Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting [PDF]
Journal of Comparative Effectiveness ResearchAim: Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) formedical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF.
Rupesh Subash +9 more
doaj +2 more sources
Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
Frontiers in Veterinary Science, 2021 Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans.
Noelle D. Herrera +5 more
doaj +1 more source
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. [PDF]
PLoS ONE, 2018 Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin.
Xiaoyan Li +11 more
doaj +1 more source
Scientific Reports, 2021 In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome.
Alenka Mavri +7 more
doaj +1 more source
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin [PDF]
Thrombosis and Haemostasis, 2016 Gregory Lip
exaly +2 more sources
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. [PDF]
PLoS ONE, 2012 BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of ...
Soyon Lee +3 more
doaj +1 more source
Idiopathic Bilateral Internal Jugular Vein Thrombosis Diagnosed by Point-of-Care Ultrasound [PDF]
, 2020 Internal jugular vein (IJV) thrombosis is an unusual condition, especially when it develops bilaterally. This is a case of bilateral IJV thrombosis in a 77-year old female who presented to the emergency department with neck and arm swelling after ...
Aquino-Jose, Victor M. +2 more
core +2 more sources
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]
, 2020 Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P +17 more
core +2 more sources